874
Characterization of Virologic Failures on Darunavir/Ritonavir in the Randomized, Controlled, Phase III TITAN Trial in Treatment-experienced Patients
Sandra De Meyer*1, E Lathouwers1, I Dierynck1, E De Paepe1, B Van Baelen1, T Vangeneugden1, S Spinosa-Guzman1, G Picchio2, and M P de Bethune1
1Tibotec BVBA, Mechelen, Belgium and 2Tibotec Inc, Yardley, PA, US

|